Who are the players?
How far along are they?
What products have already reached the market?
Which are set to emerge from the R&D pipeline?
Where are the opportunities?
This 83-page report identifies nearly 40 organizations that are developing
products or have made basic science discoveries pointing toward novel cardiovascular
IVDs. Among these are 22 private companies with active cardiovascular
IVD programs.
It also lists the organizations active in specific disease areas: heart
attack, stroke, atherosclerosis (active disease as well as risk factors
associated with future disease), heart failure, thrombosis, post-angioplasty
restenosis and gene-based diseases such as certain forms of hypertension
and arrhythmia.
Among the topics covered:
* easy-to-use, multiple-assay panels for
diagnosing heart attacks in progress
* new markers for detecting strokes, including
S-100 and neuron-specific enolase
* rapid homocysteine assays for atherosclerosis
* IVDs for diagnosing active cases of atherosclerosis
* markers of increased risk of thrombosis
* emerging risk factors for atherosclerosis,
including infectious agents, genes and new lipid
species
|
